Walgreens Boots Alliance, Inc. vs Corcept Therapeutics Incorporated: Examining Key Revenue Metrics

Revenue Growth: Walgreens vs. Corcept, 2014-2023

__timestampCorcept Therapeutics IncorporatedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 20142655100076392000000
Thursday, January 1, 201550286000103444000000
Friday, January 1, 201681321000117351000000
Sunday, January 1, 2017159201000118214000000
Monday, January 1, 2018251247000131537000000
Tuesday, January 1, 2019306486000120074000000
Wednesday, January 1, 2020353874000121982000000
Friday, January 1, 2021365978000132509000000
Saturday, January 1, 2022401858000132703000000
Sunday, January 1, 2023482375000139081000000
Monday, January 1, 2024147658000000
Loading chart...

Cracking the code

Walgreens Boots Alliance vs. Corcept Therapeutics: A Revenue Journey

In the ever-evolving landscape of the pharmaceutical and retail sectors, Walgreens Boots Alliance, Inc. and Corcept Therapeutics Incorporated stand as intriguing case studies. From 2014 to 2023, Walgreens Boots Alliance consistently demonstrated robust revenue growth, peaking at approximately $139 billion in 2023, a 22% increase from 2014. In contrast, Corcept Therapeutics, a niche player, showcased a remarkable growth trajectory, with revenues surging by over 1,700% from 2014 to 2023, reaching nearly $483 million.

This comparison highlights the diverse strategies and market positions of these companies. Walgreens, with its expansive retail network, capitalizes on scale, while Corcept focuses on specialized therapeutics. The data reveals a missing entry for Corcept in 2024, suggesting potential data gaps or reporting delays. As these companies navigate future challenges, their revenue trends offer valuable insights into their strategic directions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025